MARCO+巨噬细胞驱动化疗相关脂肪性肝炎的免疫抑制重塑与转移
该研究从10例伊立替康化疗后发生CASH的结直肠癌肝转移患者肝组织分离CD45+细胞行单细胞转录组与免疫分析,发现CASH肝脏富集免疫抑制性MARCO+巨噬细胞并伴CD8+TOX+T细胞和DNAJB1+NK细胞浸润。小鼠模型证实MARCO+巨噬细胞在脂肪性肝炎阶段出现并促进肿瘤生长和肝转移,敲除MARCO可抑制转移。
要点
- CASH肝脏免疫微环境以MARCO+巨噬细胞为核心,呈免疫抑制特征。
- MARCO+巨噬细胞浸润水平与结直肠癌患者复发率相关。
- 遗传敲除MARCO可抑制肝转移并减少CD8+TOX+T细胞浸润。
核心结论
- CASH存在以MARCO+巨噬细胞为核心的独特免疫调控网络,参与破坏肝脏抗肿瘤免疫并与高复发率相关。
- 靶向MARCO+巨噬细胞可能为减轻化疗肝损伤和开发肝转移免疫治疗策略提供新途径。
研究设计与样本
- 从10例伊立替康化疗后发生CASH的CRLM患者肝组织分离CD45+细胞,行单细胞转录组与免疫谱整合分析。
主要发现
- CASH与CRLM患者高复发率相关。
- 与无CASH患者相比,CASH患者肝脏免疫微环境富集具免疫抑制特征的MARCO+巨噬细胞。
- MARCO+巨噬细胞浸润水平与结直肠癌患者复发率相关。
- CASH微环境还伴耗竭性CD8+TOX+T细胞及高度应激活化的DNAJB1+NK细胞。
- 伊立替康诱导CASH小鼠模型中,MARCO+巨噬细胞特异性出现于脂肪性肝炎阶段而非急性肝损伤阶段,并促进肿瘤生长和肝转移。
关键数值与推荐
- 遗传敲除MARCO显著抑制CLRM并减少CD8+TOX+T细胞浸润。
临床怎么用
- CASH患者肝脏MARCO+巨噬细胞浸润可作为复发风险相关免疫指标关注。
- MARCO+巨噬细胞及下游CD8+TOX+T细胞、DNAJB1+NK细胞网络是潜在干预靶点。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Chemotherapy-associated steatohepatitis (CASH) is a common side effect of treatment in patients with colorectal liver metastases (CRLM) that may affect patient outcomes. However, the underlying mechanisms of CASH remain poorly understood. METHODS: CD45+ cells were isolated from liver tissues of 10 patients with CRLM who developed CASH following irinotecan-based chemotherapy. These cells were subjected to integrated single-cell transcriptomic and immune profiling analyses. Twenty-four pairs of human CASH samples, a clinical cohort, and irinotecan-induced CASH mouse models were used to confirm the mechanism. RESULTS: CASH is associated with high recurrence rates in patients with CRLM. Compared to patients without CASH, those with CASH exhibit an immune microenvironment enriched in MARCO+ macrophages with immunosuppressive features. The infiltration level of these macrophages correlates with recurrence rates in patients with colorectal cancer. This environment is further defined by the presence of exhausted CD8+ TOX+ T cells and highly stressed, activated DNAJB1+ NK cells. Using an irinotecan-induced CASH mouse model, we demonstrated that MARCO+ macrophages emerge specifically during the steatohepatitis phase, not the acute liver injury stage, and actively promote tumor growth and liver metastasis. Critically, genetic ablation of MARCO significantly inhibited CLRM and reduced the infiltration of CD8+ TOX+ T cells. CONCLUSIONS: This study uncovers a distinct immunoregulatory network in CASH, highlighting potential avenues to mitigate chemotherapy-associated hepatic injury and to develop novel immunotherapeutic strategies for patients with liver metastases. IMPACT AND IMPLICATIONS: Chemotherapy-associated steatohepatitis (CASH) is a common side effect of treatment in patients with colorectal liver metastases (CRLM) that may affect patient outcomes. However, the mechanisms remain poorly understood. Herein, we identify a distinct immune microenvironment in the livers of patients with CASH that is centered on MARCO+ macrophages and accompanied by increased infiltration of CD8+ TOX+ T cells and DNAJB1+ NK cells. This regulatory network participates in disrupting liver antitumor immune responses and is associated with high recurrence rates in patients with CRLM. Our findings provide potential avenues for mitigating chemotherapy side effects and developing novel immunotherapeutic strategies for patients with liver metastases.
引用
- Ding K, Mao A, Wang Y, et al. MARCO+ macrophages drive immunosuppressive remodeling and metastasis in chemotherapy-associated steatohepatitis. J Hepatol. 2025. PMID: 41274349. doi:10.1016/j.jhep.2025.11.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。